drugset
drugset / Trial / NCT01215773

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

NCT01215773 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objectives of the multiple dose study are to investigate the safety, tolerability pharmacokinetics of BI 671800 HEA in healthy male and female volunteers following multiple oral administration of BI 671800

Timeline

Start
2010-10
Primary completion
2010-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 671800 Small molecule 200 mg Oral
Subject BI 671800 Small molecule 400 mg Oral

Indications

No indication recorded.